An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by:
Biodel
ClinicalTrials.gov Identifier:
NCT00542724
First received: October 5, 2007
Last updated: January 21, 2010
Last verified: January 2010

October 5, 2007
January 21, 2010
September 2006
July 2008   (final data collection date for primary outcome measure)
Change in HbA1c
Same as current
Complete list of historical versions of study NCT00542724 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

The purpose of this study is to demonstrate equivalent blood glucose control in patients with type 1 diabetes mellitus with insulin VIAject™ and regular human insulin as prandial insulin and to demonstrate an equivalent safety profile for VIAject™ in comparison to regular human insulin.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Type 1 Diabetes Mellitus
  • Drug: VIAject™
    Dosage as individually required
  • Drug: Regular Human Insulin
    Dosage as individually required
  • Experimental: A
    VIAject™
    Intervention: Drug: VIAject™
  • Active Comparator: B
    Regular Human Insulin
    Intervention: Drug: Regular Human Insulin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
462
Not Provided
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

Male or female patients with type 1 diabetes must present with the following:

  • Established diagnosis of type 1 diabetes for more than 1 year.
  • HbA1c values of not more than 10.5%.
  • Three months on a stable insulin regimen that meets the current standard of care and that includes at least two daily insulin injections.
  • Age: 18 to 70 years.
  • Body Mass Index: 18 - 38 Kg/m2.

Exclusion Criteria:

Patients presenting with any of the following will not be included in the study:

  • Type 2 diabetes mellitus as determined by the investigator.
  • History of frequent severe hypoglycemia within the prior six months.
  • C-peptide > 1.0 ng/ml unless there is a documented history of ketoacidosis or a documented history of a positive anti GAD test.
  • History of known hypersensitivity to any of the components in the study medication.
  • History of severe or multiple allergies.
  • Treatment with investigational diabetes drug in the last 3 months or treatment with any other investigational drug in the last 30 days before study entry.
  • Current short-term treatment with systemic oral, injected, or inhaled corticosteroids. (inhaled corticosteroids may be allowed when the treatment is long-term).
  • Progressive disease likely to prove fatal.
  • History of malignancy within the past 5 years except for basal cell epithelioma.
  • Known significant hepatic disease or serum AST or ALT values ≥ 3 X upper limit of normal or bilirubin levels ≥ 1.5 X upper limit of normal.
  • Severe complications of diabetes mellitus including a history or finding of Stage III or IV diabetic retinopathy, proteinuria > 2+ by urine dipstick, serum creatinine of >1.8 mg/dl for males or >1.5 mg/dl for females, history of renal transplant, severe peripheral vascular disease which has resulted in an amputation, chronic foot ulcers claudication or absent pedal pulses.
  • Known history of autonomic neuropathy.
  • History of moderate to severe ketoacidosis within the 3 months preceding screening for the study.
  • Current drug or alcohol abuse, or a history which in the opinion of the Investigator will impair patient safety or protocol compliance.
  • Current significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the Investigator.
  • Blood donation within the last 30 days.
  • A woman who is breast feeding.
  • Pregnant women or women intending to become pregnant during the study.
  • A sexually active woman of childbearing age not actively and consistently practicing birth control by using a medically accepted device or therapy.
  • Abnormal ECG, safety lab or physical examination results which, in the opinion of the investigator, render the participation of the patient in the study to be inappropriate or unsafe.
  • A history of lack of compliance with medical instructions, recent drug or alcohol abuse, or other reasons which, in the opinion of the investigator, render the participation of the patient in the study to be inappropriate or unsafe.
  • Current significant diseases of the adrenal gland, pituitary gland or thyroid at the discretion of the investigator.
  • Glomerular Filtration Rate < 40 ml/min.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00542724
VIAject™-06J
No
Biodel
Biodel
Not Provided
Principal Investigator: David C Klonoff, M.D., F.A.C.P. University of Miami
Biodel
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP